May 24, 2022 / 11:00AM GMT
Thomas Yip - H.C. Wainwright & Co., LLC - Analyst
Hello, everyone. Welcome to the 2022 HC Wainwright Global Investment Conference. This is Thomas Yip from H.C. Wainwright. For our next presentation, we have Mr. Jesse Shefferman, CEO of Protara Therapeutics, a clinical-stage company, developing treatments for oncology and other rare diseases.
Jesse, very happy to have you with us today. Please go ahead.
Jesse Shefferman - Protara Therapeutics, Inc. - Co-Founder, Director & CEO
Thanks, Thomas, and thank you to the broader Wainwright team for having us on. I'm going to start with just a quick scan through, an overview of Protara, and then we'll jump right into where we will spend the majority of our time, which is on TARA-002, our lead candidate for bladder cancer and lymphatic malformations.
So who is Protara? We, as you mentioned, are a oncology and rare disease focused company. We're based in New York City. And our lead program, TARA-002, is a bacterial immunopotentiator, based on an originator therapy used for oncology for over 40
Protara Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) - On-Demand Transcript
May 24, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers